# Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus

> **NCT04272359** · — · UNKNOWN · sponsor: **University of Milan** · enrollment: 138 (estimated)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)
- Diet, Healthy
- Renal Function Disorder
- Albuminuria

## Interventions

- **DRUG:** Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas

## Key facts

- **NCT ID:** NCT04272359
- **Lead sponsor:** University of Milan
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-06
- **Primary completion:** 2021-10-06
- **Final completion:** 2021-12-31
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272359, "Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04272359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*